Redeye leaves a comment on the Q1 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, we are encouraged by the clinical and financial progress. | May 17, 2023
Alzinova AB completed a rights issue of units on Nasdaq First North Growth Market in June 2022. One unit consisted of five shares and four warrants of series TO3 . Each Warrant gives the right to. | April 5, 2023
/PRNewswire/ Alzinova AB (publ) ("Alzinova" or "the Company"), announces today that a second external safety review has been carried out of the Company s.
STOCKHOLM, April 28, 2022 /PRNewswire/ Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments for Alzheimer's disease by specifically targeting neurotoxic amyloid